KrishPatelMD

Oncology • Seattle, WA

Hematologic Oncology

Director of Lymphoma Program Director of Hematology and Cell Therapy Swedish Cancer Institute

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Patel's full profile

Already have an account?

Office
1221 Madison St
Ste 1020
Seattle, WA 98104
Phone+1 206-215-6196

Fax+1 206-215-1655
Is this information wrong?

Summary

I am a board certified hematologist & medical oncologist who specializes in hematologic malignancies & cellular therapies. I have a particular focus in the care of patients with lymphoma & CLL and actively participate in developing novel therapies for these patients through early stage clinical trials.

I am also engaged in clinical research to develop cellular therapies in hem & solid tumor onc.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2016
Duke University HospitalResidency, Internal Medicine, 2009 - 2012
Duke University School of MedicineClass of 2009

Certifications & Licensure

WA State Medical License 2016 - 2025
NC State Medical License 2009 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Alpha Omega Alpha
Chief Resident, Internal Medicine, Duke University Hospital Duke University Hospital, 2013-2014
NIH Clinical Research Training Program National Institutes of Health - NCI, 2007-2008

Clinical Trials

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Start of enrollment: 2012 Dec 01
Completed
Phase 1
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Feb 28
Completed
Phase 2
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers Start of enrollment: 2017 Apr 28
Terminated
Phase 1, Phase 2
A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Start of enrollment: 2017 Dec 28
Recruiting
Phase 1, Phase 2
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma Start of enrollment: 2018 Jun 07
Active, not recruiting
Phase 1
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL Start of enrollment: 2019 Aug 16
Recruiting
Phase 2
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Start of enrollment: 2019 Mar 14
Completed
Phase 1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 2
FT516 in Subjects With Advanced Hematologic Malignancies Start of enrollment: 2019 Oct 04
Terminated
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2019 Aug 13
Recruiting
Phase 1
Oral Tazemetostat in Combination With Rituximab in R/R FL Start of enrollment: 2020 Nov 17
Terminated
Phase 2
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Start of enrollment: 2021 May 05
Active, not recruiting
Phase 1
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies Start of enrollment: 2020 Mar 19
Terminated
Phase 1
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Start of enrollment: 2021 Sep 30
Active, not recruiting
Phase 1
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2022 Jan 20
Active, not recruiting
Phase 1
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Start of enrollment: 2022 Apr 15
Terminated
Phase 2
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2018 Nov 16
Active, not recruiting
Phase 1, Phase 2
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Start of enrollment: 2020 Dec 15
Terminated
Phase 2
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies Start of enrollment: 2023 Jan 24
Recruiting
Phase 1
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL Start of enrollment: 2021 Dec 15
Completed
Phase 2
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases Start of enrollment: 2023 Sep 13
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Start of enrollment: 2021 May 26
Recruiting
Phase 1
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Start of enrollment: 2022 Jun 14
Recruiting
Phase 2
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product Start of enrollment: 2024 Apr 29
Recruiting
Roles: Contact
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

22 citations
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel, Toby A Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S Tam, Nirav N Sh...> ;The New England Journal of Medicine. 2023 Jul 6
5 citations
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Michael L Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A Eyre, Chan Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian Flinn, Benoit Tessouli...> ;Journal of Clinical Oncology. 2023 Aug 20
Treatment selection for patients with relapsed or refractory follicular lymphoma.
Alan Z Skarbnik, Krish Patel> ;Frontiers in Oncology. 2023 Jan 1
15 citations
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.
John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, William G Wierda, Michael Y Choi, Susan M O'Brien, Mazyar Shadman, Matthew S Davi...> ;Haematologica. 2022 Apr 1
6 citations
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L Bartlett, Mary-Kate Malecek, Marcus P Watkins, Kami J Maddocks, David A Bond,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
15 citations
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas Stauffer Larsen, Krish Patel, Ulrich Jäger, Robert Manges, Lorenz Trümper, Hele Everaus, Nagesh Ka...> ;International Journal of Hematology. 2021 Nov 19
20 citations
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Hamood Alqahtani, Michael Y. Choi, Michae...> ;Clinical Cancer Research. 2021 Jun 24
34 citations
Current and future treatment strategies in chronic lymphocytic leukemia.
Krish Patel, John M. Pagel> ;Journal of Hematology & Oncology. 2021 Apr 26
10 citations
Baseline Demographics and Clinical Characteristics Among 3471 US Patients Hospitalized with COVID-19 and Pulmonary Involvement: A Retrospective Study.
Jennie H. Best, Shalini V. Mohan, Amanda M. Kong, Krish Patel, John M. Pagel, Boris Ivanov, Otis W. Brawley, Krutika Jariwala-Parikh, James L. Zazzali, John S Pauk> ;Advances in Therapy. 2020 Oct 12
220 citations
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood. 2020 Sep 3
95 citations
Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.
Livia Hegerova, Ted Gooley, Kelly A Sweerus, Cynthia L Maree, Neil Bailey, Megumi Bailey, Vanessa Dunleavy, Krish Patel, Kirsten Alcorn, N. Rebecca Haley, Jill M. John...> ;Blood. 2020 Aug 6
20 citations
Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.
Krish Patel, Ted Gooley, Neil Bailey, Megumi Bailey, Livia Hegerova, Ami Batchelder, Heather Holdread, Vanessa Dunleavy, Tyler Downey, Jens Frisvold, Samantha Megrath,...> ;Journal of Internal Medicine. 2021 Mar 1
30 citations
COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.
Matthew E. Hartman, Roland A. Hernandez, Krish Patel, Teresa E. Wagner, Tony Trinh, Anne B Lipke, Eric T. Yim, Juan N. Pulido, John M. Pagel, Samuel Youssef, John L. M...> ;ASAIO Journal. 2020 Jun 1
3 citations
A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study
Max J. Gordon, Andrea Sitlinger, Tareq Salous, Hamood Alqahtani, Michael C. Churnetski, Xavier Rivera, Paul Wisniewski, Jonathon Cohen, Krish Patel, Mayzar Shadman, Mi...> ;Leukemia Research. 2020 Jan 21
26 citations
Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma
Krish Patel, Alexey V. Danilov, John M. Pagel> ;Blood. 2019 Nov 7
14 citations
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Krish Patel, John M. Pagel> ;Current Hematologic Malignancy Reports. 2019 Aug 1
5 citations
Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among...
Krish Patel, Vinjamuri Sai Sudhir, Shaum M Kabadi, Joanna C Huang, Sanchita Porwal, Kushan Thakkar, John M. Pagel> ;Journal of Oncology Pharmacy Practice. 2019 Feb 5
11 citations
Febrile Neutropenia.
Krish Patel, Howard Jack West> ;JAMA Oncology. 2017 Dec 1
15 citations
Development and Refinement of a Learning Health Systems Training Program.
Nicholas G. Wysham, Lynn Howie, Krish Patel, C. Blake Cameron, Gregory P. Samsa, Laura Roe, Amy P. Abernethy, Aimee K. Zaas> ;EGEMS. 2016 Nov 16
7 citations
Febrile Neutropenia Rates in Men Treated with Docetaxel Chemotherapy for Metastatic Hormone-sensitive Prostate Cancer
J Mahil, C. Hughes, Krish Patel, Jeanette Lyons, P.A. Elliott, Ananya Choudhury, Ruth Conroy> ;Clinical Oncology. 2016 Sep 1
1 citations
Prevalence and impact of correlative science in breast cancer phase II trials
Tian Zhang, Andrew B. Schneider, Erika Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, Jeffrey Peppercorn> ;Breast Cancer Research and Treatment. 2013 Jun 15
611 citations
SIRT3 Is a Mitochondria-Localized Tumor Suppressor Required for Maintenance of Mitochondrial Integrity and Metabolism during Stress
Hyun-Seok Kim, Krish Patel, Kristi Muldoon-Jacobs, Kheem S. Bisht, Nukhet Aykin-Burns, J. Daniel Pennington, Riet van der Meer, Phuongmai Nguyen, Jason E. Savage, Kjer...> ;Cancer Cell. 2010 Jan 19
36 citations
CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Phuongmai Nguyen, Hengmi Cui, Kheem S. Bisht, Lunching Sun, Krish Patel, Richard S. Lee, Hiroyuki Kugoh, Mitsuo Oshimura, Andrew P. Feinberg, David Gius> ;Cancer Research. 2008 Jul 15
Join now to see all

Books/Book Chapters

Oncologic Emergency Medicine: Principles and Practice
Chapter: Rapid Learning Systems
Page 79 - 93Patel K, Abernethy A, Todd HK, Thomas Jr CRSpringer International Publishin

Abstracts/Posters

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Patel Krish, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

$Xencor Presents Data from Plamotamab Phase 1 Study in Relapsed or Refractory Non-Hodgkin’s Lymphoma at American Society of Hematology Annual Meeting$
Xencor Presents Data from Plamotamab Phase 1 Study in Relapsed or Refractory Non-Hodgkin’s Lymphoma at American Society of Hematology Annual MeetingDecember 12th, 2022
$Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting$
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual MeetingDecember 12th, 2022
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual MeetingDecember 12th, 2021
Join now to see all